ALLERGAN PLC's ticker is AGN and the CUSIP is G0177J108. A total of 1,056 filers reported holding ALLERGAN PLC in Q4 2017. The put-call ratio across all filers is 1.43 and the average weighting 0.5%.
About ALLERGAN PLC
Allergan PLC is a global pharmaceutical company that specializes in developing, manufacturing, and marketing branded pharmaceuticals, medical aesthetics, biosimilars, and over-the-counter consumer products. The company is headquartered in Dublin, Ireland, and has operations in more than 100 countries worldwide.
Allergan's portfolio includes a wide range of products, including Botox, Juvederm, and CoolSculpting, which are used for medical aesthetics. The company also produces a number of prescription drugs, including treatments for eye care, central nervous system disorders, and gastrointestinal diseases.
In recent years, Allergan has faced some challenges, including the loss of patent protection for some of its key products. However, the company has continued to invest in research and development, and has made a number of strategic acquisitions to strengthen its portfolio.
One of the most significant developments for Allergan in recent years was its acquisition by AbbVie, which was completed in May 2020. The acquisition was valued at approximately $63 billion and created a leading global pharmaceutical company with a diverse portfolio of products.
Looking ahead, Allergan is well-positioned to continue its growth and success in the pharmaceutical industry. With a strong portfolio of products, a commitment to research and development, and the support of AbbVie, the company is poised to deliver value to its shareholders and make a positive impact on the lives of patients around the world.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $31,033,000 | -7.3% | 184,400 | -7.8% | 0.11% | -2.8% |
| Q2 2019 | $33,470,000 | -28.0% | 199,904 | -37.0% | 0.11% | -29.7% |
| Q1 2019 | $46,462,000 | +26.5% | 317,344 | +15.5% | 0.16% | +15.7% |
| Q4 2018 | $36,727,000 | -41.2% | 274,782 | -16.2% | 0.13% | -22.5% |
| Q3 2018 | $62,480,000 | +150.5% | 328,011 | +119.2% | 0.17% | +137.0% |
| Q2 2018 | $24,944,000 | +56.4% | 149,619 | +57.9% | 0.07% | +55.3% |
| Q1 2018 | $15,945,000 | -49.3% | 94,748 | -50.8% | 0.05% | -47.8% |
| Q4 2017 | $31,471,000 | -39.1% | 192,386 | -23.7% | 0.09% | -40.4% |
| Q3 2017 | $51,665,000 | +30.4% | 252,085 | +54.7% | 0.15% | +28.0% |
| Q2 2017 | $39,614,000 | -11.6% | 162,963 | -16.3% | 0.12% | -13.9% |
| Q3 2016 | $44,819,000 | +22.4% | 194,603 | +22.8% | 0.14% | +19.1% |
| Q2 2016 | $36,615,000 | -59.3% | 158,445 | -52.2% | 0.12% | -57.7% |
| Q3 2015 | $90,028,000 | -29.2% | 331,216 | -20.9% | 0.27% | -18.8% |
| Q2 2015 | $127,131,000 | – | 418,939 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burren Capital Advisors Ltd | 30,117 | $5,334,000 | 66.38% |
| PSquared Asset Management AG | 1,897,165 | $335,988,000 | 61.77% |
| Twin Securities, Inc. | 667,224 | $118,165,000 | 60.46% |
| MASON CAPITAL MANAGEMENT LLC | 921,000 | $163,109,000 | 51.88% |
| Tibra Equities Europe Ltd | 18,613 | $3,296,000 | 50.50% |
| First Trust Capital Management L.P. | 526,853 | $93,305,000 | 48.01% |
| SYQUANT CAPITAL SAS | 1,080,922 | $191,431,000 | 47.02% |
| Boussard & Gavaudan Investment Management LLP | 1,148,847 | $204,288,000 | 44.31% |
| GWM Asset Management Ltd | 285,070 | $50,486,000 | 39.30% |
| Athos Capital Ltd | 285,500 | $50,562,000 | 35.06% |